In gliomas, IDH1 mutation explains the adverse prognostic effect of older age18,19, while in intrahepatic cholangiocarcinoma patients with mutant IDH, there was no direct association with clinical outcome34. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.